Page 2 - Transform Patient News Today

Phase 2 study shows 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 62% relative reduction in the rate of decline in percent predicted forced vital capacity versus... | May 22, 2023

PRINCETON - Bristol Myers Squibb today announced that the European Commission has approved Sotyktu , a first-in-class, selective tyrosine kinase 2 inhibitor, for the treatment of adults with... | March 29, 2023

Sotyktu demonstrated superior efficacy in improving skin clearance over placebo and twice-daily Otezla® , with a well-tolerated safety profile, in the pivotal Phase 3 POETYK PSO clinical... | March 28, 2023

/PRNewswire/ -- Equality Health, a leading provider of value-based physician networks uniquely equipped to address the needs of diverse and historically...

Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasisNew analysis to be presented at the 2022 European Academy of Dermatology and Venereology Cong...

Results showed improved or preserved cognitive function in a majority of people regardless of baseline values, with the greatest effect observed in almost 80% of people with high thalamic volume (45.5%

Press release content from Business Wire. The AP news staff was not involved in its creation.

Deucravacitinib showed statistically significant efficacy at primary endpoint of Systemic Lupus Erythematosus (SLE) Responder Index-4 (SRI(4)) responses versus placebo at Week 32 Secondary endpoints

South Carolinas only comprehensive academic health sciences center deploys Notable’s intelligent automation platform to expand access...